

4 March 2024

## Completion of Consolidation of Capital

**Osteopore Limited (ASX: OSX; Osteopore or Company)**, a global regenerative medicine company founded in Singapore and listed in Australia, is pleased to advise that the consolidation of capital approved by shareholders at the Company's general meeting on 21 February 2024, has been completed.

The Company's post consolidation capital structure is as follows:

Quoted Securities	ASX Code	Number
Ordinary fully paid shares	OSX	10,328,689
Options expiring 24 April 2026 exercisable at \$3.375 each	OSXO	3,510,164

Unquoted Securities	ASX Code	Number
Options expiring 2 November 2025 exercisable at \$9.36 each	OSXAI	12,500

Performance Rights	ASX Code	Number
Performance Rights	OSXAK	900,004

New holding statements will be despatched to security holders advising them of their securities held on a post-consolidation basis. Where the consolidation has resulted in a fraction of a security held, that fraction has been rounded up to the nearest whole security.

**ENDS**

*This announcement dated 4 March 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.*



For more information, please contact:

**Mark Leong**

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: [istewart@canningspurple.com.au](mailto:istewart@canningspurple.com.au)

**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia aiming to commercialise products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time only to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

**Forward-Looking Statements**

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

